Wegovy Pill (Oral Semaglutide) — Where to Get It Online in 2026
On December 22, 2025, the FDA approved Novo Nordisk's oral Wegovy (semaglutide 25 mg tablets) for chronic weight management — the first oral GLP-1 ever approved for an obesity indication in the US. This is a different product from Rybelsus, which has been on the market since 2019 but tops out at 14 mg and is approved only for type 2 diabetes. The pivotal OASIS 4 trial reported −16.6% mean body-weight loss at 64 weeks in adherent participants on the 25 mg dose — figures that put it on roughly the same efficacy plane as injectable Wegovy 2.4 mg without a head-to-head trial to confirm parity. As of writing, FuturHealth is the only consumer telehealth platform we have verified is actively dispensing the Wegovy pill at scale.
Rankings combine clinical formulary depth, pricing transparency, and shipping reliability — weighted equally and reviewed quarterly. Read the full methodology →
Semaglutide 25 mg in oral tablet form, formulated with the SNAC absorption enhancer (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) — the same delivery technology used in Rybelsus. The 25 mg obesity-indicated dose is roughly 1.8× the highest Rybelsus diabetes dose. Mechanistically identical to injectable Wegovy: a long-acting GLP-1 receptor agonist that slows gastric emptying, increases satiety, and reduces caloric intake. The differentiator is route, not molecule.
Adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidaemia, OSA), who prefer a daily oral tablet to a weekly injection. The tablet form is most useful for needle-averse patients, frequent travellers who don't want to manage refrigerated pens, and patients who already take other once-daily morning medications and can absorb the fasted-window protocol into an existing routine.
Titration follows a four-step, ~16-week schedule: 1.5 mg (days 1–30) → 4 mg (days 31–60) → 9 mg (days 61–90) → 25 mg maintenance (day 91+), escalating roughly every 30 days if tolerated. The fasted-window protocol is strict: the tablet must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before eating, drinking anything other than water, or taking any other oral medication. Coffee, supplements, and most other oral meds break the absorption window.
Providers That Prescribe wegovy
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
What the Studies Actually Show
The evidence below comes from the OASIS 4 trial (the pivotal study for the December 2025 FDA approval of oral semaglutide 25 mg for weight management) and the FDA prescribing information. OASIS 4 data are from the adherent-participant analysis presented at EASD 2025.
| Endpoint | Finding |
|---|---|
| Mean weight loss (OASIS 4, 64 weeks, 25 mg once-daily)1 | −16.6% body weight with full adherence vs −2.7% placebo in adults with obesity |
| Participants achieving ≥20% weight loss (OASIS 4, adherent subset)1 | One-third of adherent participants achieved ≥20% weight loss vs <3% on placebo |
| Serious adverse events (OASIS 4)1 | 3.9% with oral semaglutide vs 8.8% with placebo — fewer serious events in the treatment arm |
| Prediabetes reversal (OASIS 4 post-hoc)1 | 71.1% of participants with prediabetes at baseline achieved normal blood glucose by week 64 |
| Cardiovascular risk factors (OASIS 4 post-hoc)1 | Improvements in blood pressure, glycemic control, and composite cardiovascular risk markers observed alongside weight loss |
| FDA approval date2 | December 22, 2025 — first oral GLP-1 receptor agonist approved specifically for chronic weight management in adults (not just type 2 diabetes) |
| Dosing2 | Once-daily oral tablet; titration from 1.5 mg → 4 mg → 12 mg → 25 mg over approximately 20 weeks. Must be taken on an empty stomach with ≤4 oz water, 30 min before food/drink/other medications |
| How it differs from injectable Wegovy1 | Same active ingredient (semaglutide) but oral route. Injectable Wegovy 2.4 mg weekly achieved −14.9% in STEP 1; oral 25 mg daily achieved −16.6% in OASIS 4 — broadly comparable efficacy, different administration route Direct head-to-head trial between oral and injectable Wegovy has not been published. OASIS 4 and STEP 1 used different populations and protocols; cross-trial comparisons are approximate. |
| How it differs from Rybelsus (oral semaglutide for diabetes)2 | Rybelsus is approved for type 2 diabetes at doses up to 14 mg. Wegovy tablets are approved for chronic weight management at 25 mg — a higher dose with a distinct obesity indication |
Frequently Asked Questions
Is the Wegovy pill the same as Rybelsus?
No, and it is not just a renamed Rybelsus. Both products contain semaglutide and use the SNAC absorption enhancer, but Rybelsus is approved only for type 2 diabetes and tops out at 14 mg/day. Wegovy tablets are approved specifically for chronic weight management and dose to 25 mg/day. The 25 mg strength was not previously available in any oral GLP-1 product, and the obesity indication is what unlocks the larger affected patient population.
Is the Wegovy pill as effective as the Wegovy injection?
On available data, broadly yes — but the comparison is indirect. OASIS 4 reported −16.6% mean body-weight loss at 64 weeks in adherent participants on 25 mg daily; STEP 1 reported −14.9% at 68 weeks on injectable 2.4 mg weekly. Different trials, different populations, different durations, no head-to-head RCT. Real-world results will hinge on adherence to the 30-minute fasted window — a much higher daily compliance burden than a weekly injection.
Which telehealth providers prescribe the Wegovy pill?
As of mid-2026, FuturHealth has the most accessible direct telehealth path — a flat $198/mo coaching subscription bundled with medication access. Novo Nordisk's NovoCare cash channel provides direct fulfilment for self-pay patients (~$149/mo for 1.5 mg and 4 mg starter doses; higher for the 25 mg maintenance), with retail dispensing through Costco Pharmacy, Amazon Pharmacy, and Walmart. Most major GLP-1 telehealth platforms (Ro, Hims, Henry, Eden) had not added oral Wegovy to their public formularies at the time of writing; expect that to change as supply normalises.
Will compounding pharmacies make oral semaglutide for weight loss?
They cannot legally do so for the obesity indication. Compounded GLP-1s have always relied on the FDA's drug-shortage exemption or the personalisation exception. Now that brand-name oral semaglutide for weight loss is FDA-approved and commercially available, neither pathway applies. Any platform marketing 'compounded oral Wegovy' or 'compounded oral semaglutide for weight loss' in 2026 is operating outside the FDA framework. Compounded oral dissolving semaglutide for diabetes off-label use is a separate regulatory question.
Does insurance cover the Wegovy pill?
Coverage tracks injectable Wegovy closely. Plans that cover Wegovy for obesity will generally extend to the tablet; plans that exclude obesity-indicated GLP-1s will exclude both. The NovoCare savings card can reduce commercial copays meaningfully. For uninsured patients, NovoCare cash-pay starts at $149/mo for the 1.5 mg and 4 mg titration doses (4 mg at promotional rate through August 2026) — currently the cheapest legitimate route during the early dose-escalation phase.
Can I switch from injectable Wegovy to the tablet?
Yes, under clinician supervision. There is no published 1:1 dose conversion. Standard practice is to restart oral titration at a low dose (typically 4 mg) rather than jumping straight to 25 mg, even for patients who are stable on injectable 2.4 mg. The titration takes weeks, so the switch carries some weight-regain risk during the transition unless overlap is managed deliberately.
- OASIS 4 — Novo Nordisk press release / GlobeNewswire 2025 · Novo Nordisk. Oral semaglutide 25 mg delivered 16.6% weight loss in people with obesity in the OASIS 4 trial. GlobeNewswire, September 17, 2025.
- FDA approval — Novo Nordisk press release, December 22 2025 · Novo Nordisk. FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults. PR Newswire, December 22, 2025.
- FDA prescribing information — Wegovy tablets (semaglutide 25 mg) · U.S. Food and Drug Administration. Wegovy (semaglutide) tablets prescribing information. NDA 218316. December 2025.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.